Skip to Content

Edsivo Approval Status

FDA Approved: No
Brand name: Edsivo
Generic name: celiprolol
Company: Acer Therapeutics Inc.
Treatment for: Vascular Ehlers-Danlos Syndrome

Edsivo (celiprolol) is a β-blocker (β1-andrenoceptor antagonist with partial β2 agonist activity) in development for the treatment of vascular Ehlers-Danlos syndrome (vEDS).

Development Status and FDA Approval Process for Edsivo

DateArticle
Jun 25, 2019Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of Edsivo (celiprolol) in vEDS Patients
Oct 29, 2018Acer Therapeutics Submits NDA for Edsivo (celiprolol) for the Treatment of Vascular Ehlers-Danlos syndrome (vEDS)
Sep 25, 2017Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial of Edsivo (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide